Relfydess 100iu Per ml x10 Vials

Relfydess ▼

Relabotulinum Toxin Type A

Defining A New Standard In The Temporary Improvement & Appearance Of Moderate-To-Severe Wrinkles

Relfydess™, developed by Galderma, represents a significant advancement in aesthetic medicine as a ready-to-use liquid neuromodulator. Designed for precision and simplicity, it combines high efficacy with a well-tolerated safety profile, offering a new benchmark in both performance and purity.

Formulated using PEARL™ Technology, Relfydess™ is engineered for enhanced biological activity and refined purity. In clinical studies, up to 39% of patients reported visible improvement from Day 1, with up to 75% maintaining results through 6 months (References 1–3). The formulation is free from complexing proteins and contains no human- or animal-derived components, supporting a cleaner, more consistent treatment profile.

Patients report high satisfaction with the outcomes, with up to 98% indicating they would return for repeat treatment, reinforcing both the aesthetic benefits and the overall treatment experience.

PEARL™ Technology: The Innovation Behind Relfydess™

At the core of Relfydess™ is a proprietary bacterial strain utilizing PEARL™ Technology. This process ensures full control of the manufacturing pathway and delivers a highly active neuromodulator containing only the essential components.

Unlike conventional formulations, PEARL™ Technology maintains the molecule in liquid form from start to finish, preserving potency and integrity without the need for reconstitution. The refinement process is deliberately gentle, removing complexing proteins and impurities while maintaining efficacy and stability.

Together, Relfydess™ and PEARL™ Technology offer healthcare professionals a novel solution designed to simplify administration, optimize patient outcomes, and raise the standard of care in aesthetic treatment.

Relfydess®▼(Relabotulinumtoxin A) is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology, developed and manufactured by Galderma.
Relfydess® is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines and lateral canthal lines.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See ‘Undesirable Effects’ for how to report adverse reactions.

Prescribing Information & Adverse Events Reporting

Relfydess_Botulinum_toxin_type_A_solution_for_injection_PI_UK_March_2025.pdf

REFERENCES: 1. Galderma. [Relfydess] Summary of Product Characteristics. 2024. 2. Galderma Laboratories. MA-47072. Clinical Study Report for Protocol 43QM1602: READY-1. Fort Worth, TX: 2021. 3. Galderma Laboratories. MA-47073. Clinical Study Report for Protocol 43QM1901: READY-2. Fort Worth, TX: 2021.

Each Pack Contains

• x10 1.5ml vials
• 100iu Per ml

More Information

• Prescribing Information & Adverse Events Reporting
• Product Information
• Relfydess 100iu Per ml x1 Vials

Manufacturer

• Galderma